Sekkei Bio Profile
Key Indicators
- Authorised Capital ₹ 2.15 M
- Paid Up Capital ₹ 0.21 M
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -16.67%
- Profit Growth -126.25%
- Ebitda -63.00%
- Net Worth -232.43%
- Total Assets 69.26%
About Sekkei Bio
Sekkei Bio Private Limited (SBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 28 November 2017 (Seven years and two months 30 days old ). Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.15 M and a paid-up capital of Rs 0.21 M, as per Ministry of Corporate Affairs (MCA) records.
Ranganathan Anirudh, Gauri Khedkar, Monalisa Chatterji, and One other member serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999TN2017PTC130748
- Company No.
130748
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sekkei Bio?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Monalisa Chatterji  | Director | 28-Nov-2017 | Current |
| Gauri Khedkar | Director | 23-Mar-2019 | Current |
| Anand Khedkar | Director | 28-Nov-2017 | Current |
| Ranganathan Anirudh | Director | 11-Jun-2021 | Current |
Financial Performance of Sekkei Bio.
Sekkei Bio Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 16.67% decrease. The company also saw a substantial fall in profitability, with a 126.25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 232.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sekkei Bio?
In 2020, Sekkei Bio had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Explorer Tribe (Opc) Private LimitedGauri Khedkar is a mutual person
- Inbiocognate Life Sciences Private Limited
Gauri Khedkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sekkei Bio?
Unlock and access historical data on people associated with Sekkei Bio, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sekkei Bio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sekkei Bio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.